证券代码：600420 证券简称：国药现代 公告编号：2024-067 上海现代制药股份有限公司 关于获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）收到国家药品监督管理 局核准签发的《药品补充申请批准通知书》，批准普伐他汀钠片新增 40mg 品规， 并视同通过仿制药质量与疗效的一致性评价（以下简称一致性评价），核发药品 批准文号。现将相关情况公告如下： 一、药品基本信息 药品名称：普伐他汀钠片 通知书编号：2024B03622 注册分类：化学药品 药品批准文号：国药准字 H20247186 上市许可持有人：上海现代制药股份有限公司 药品生产企业：上海现代制药股份有限公司 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。同意本品增加 40mg 规格，核发新的药品批准文号。 二、药品研发及市场情况 普伐他汀钠片为竞争性抑制剂，可以抑制 HMG-CoA 还原酶，从而抑制胆固 醇的生物合成，适用于原发性高胆固醇血症或合并有高甘油三酯血症的患者（Ⅱa ...

Investment Rating - The report maintains a "Buy" investment rating for the company [1][2]. Core Views - The company continues to experience high growth despite a 7.52% year-on-year decline in revenue for H1 2024, with net profit attributable to shareholders increasing by 108.29% [1]. - The company's operational efficiency is improving, particularly in the raw material drug business, which has shown significant profit elasticity [1]. - The report forecasts revenue growth for 2024-2026, with expected revenues of 112.85 billion, 117.35 billion, and 122.62 billion respectively, and net profits of 11.61 billion, 13.76 billion, and 15.50 billion [2]. Summary by Sections Financial Performance - In H1 2024, the company achieved operating revenue of 59.60 billion, a decrease of 7.52% year-on-year, while net profit attributable to shareholders reached 6.83 billion, reflecting a growth of 108.29% [1]. - The raw material drug segment saw a revenue increase of 5.54% year-on-year, with net profit rising to 4.3 billion from 0.26 billion in the previous year [1]. - The overall gross margin for the raw material and intermediate drug segment was 32.29%, an increase of 10.97 percentage points compared to the previous year [1]. Segment Analysis - The formulation segment faced pressure with a revenue decline of 14.88% year-on-year, attributed to price reductions from centralized procurement [1]. - The narcotic platform showed stable growth, with revenue of 3.39 billion, a year-on-year increase of 20.48% [1]. Profitability Forecast - The report predicts a significant increase in net profit for 2024, with a growth rate of 67.8%, followed by 18.6% in 2025 and 12.6% in 2026 [4]. - The earnings per share (EPS) are projected to be 0.87, 1.03, and 1.16 for the years 2024, 2025, and 2026 respectively [2][4]. Market Position - The company is positioned as a core platform for the development of chemical pharmaceuticals under the China National Pharmaceutical Group, focusing on internal R&D and external collaborations to enhance its product line [2].

证券代码：600420 证券简称：国药现代 公告编号：2024-064 上海现代制药股份有限公司 关于控股子公司获得化学原料药上市申请批准通知书 的公告 化学原料药名称：维生素 K1 登记号：Y20220001273 化学原料药注册标准编号：YBY70332024 包装规格：5kg/瓶 生产企业：上海现代哈森（商丘）药业有限公司 企业地址：商丘市梁园产业集聚区新兴路 166 号 通知书有效期：至 2029 年 8 月 25 日 申请事项：境内生产化学原料药上市申请 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）控股子公司上海现代哈 森（商丘）药业有限公司（以下简称国药哈森）收到国家药品监督管理局核准签 发的维生素 K1 的《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、化学原料药基本情况 三、对公司的影响及风险提示 本次国药哈森的维生素 K1 原料药获得《化学原料药上市申请批准通知书》， 表明该原料药符合国家相关药品审批技术标准，可以进行生产销售，将进一步丰 富公司 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 CNY per 10 shares, totaling 134,117,269.20 CNY (including tax) based on the total share capital of 1,341,172,692 shares as of June 30, 2024[3]. - The company plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares, totaling 134,117,269.20 yuan (including tax) based on the total share capital of 1,341,172,692 shares as of June 30, 2024[52]. Financial Performance - The company's operating revenue for the first half of the year was ¥5,960,093,922.86, a decrease of 7.52% compared to the same period last year[7]. - Net profit attributable to shareholders increased by 108.29% to ¥718,477,263.45, while the net profit after deducting non-recurring gains and losses rose by 112.13% to ¥683,409,070.03[7]. - The net cash flow from operating activities surged by 99.30% to ¥1,817,007,399.22, indicating improved cash management[18]. - Basic earnings per share increased by 87.31% to ¥0.5357, with diluted earnings per share reflecting the same growth[17]. - The company's total assets reached ¥19,969,316,497.54, up 3.19% from the end of the previous year, while net assets attributable to shareholders rose by 4.72% to ¥12,972,609,310.33[16]. - The overall gross profit margin improved by 0.46 percentage points year-on-year, driven by a shift in product mix and cost control measures[18]. - The company achieved operating revenue of 5.96 billion yuan in the first half of 2024, a year-on-year decrease of 7.52%[23]. - Net profit attributable to shareholders reached 718 million yuan, representing a year-on-year increase of 108.29%[23]. - The gross margin for the pharmaceutical intermediates and raw materials segment improved to 32.29%, an increase of 10.97 percentage points compared to the previous year[24]. - The company achieved a net profit attributable to shareholders of the listed company, increasing by 108.29% year-on-year[32]. - The weighted average return on net assets rose by 2.44 percentage points year-on-year, indicating improved profitability quality[32]. - The asset-liability ratio decreased to 24.44%, down by 1.47 percentage points from the beginning of the period, reflecting a stronger financial position[32]. Risk Management - There are no significant risks that could materially affect the company's operations during the reporting period[5]. - The company has outlined potential risks and countermeasures in the management discussion and analysis section[5]. - The company faces market competition risks due to the high number of competing brands in the chemical generic drug sector[45]. - The company is addressing industry policy risks by accelerating strategic planning and enhancing compliance management[46]. - The company aims to increase R&D investment and improve innovation capabilities to mitigate technology innovation risks[46]. - The company is committed to improving environmental protection measures and safety management in response to safety and environmental risks[46]. - The company is enhancing quality control measures to adapt to stricter regulatory requirements in the pharmaceutical industry[47]. Corporate Governance - The financial report has been declared accurate and complete by the company's responsible persons[2]. - The board of directors and supervisory board members have all attended the board meeting[2]. - The report has not been audited[2]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[5]. - The company has not faced any violations of decision-making procedures regarding external guarantees[5]. - The company has established a comprehensive compliance management system, enhancing its risk control capabilities[37]. - The company has appointed new financial director and board secretary, indicating changes in senior management[49]. - The company has experienced changes in its executive team, with resignations and appointments occurring in 2024[50]. Operational Efficiency - The company has implemented a comprehensive procurement management system to control costs and ensure quality, enhancing operational efficiency[21]. - The company is actively pursuing digital transformation and automation in production processes to improve efficiency and quality[24]. - The company is focusing on enhancing its marketing management and has reduced sales expense ratio by 7.41 percentage points year-on-year[25]. - The company has implemented 235 quality improvement projects and 31 supply chain value stream analysis projects to enhance efficiency[37]. Environmental Responsibility - The company has established a complete regulatory operation system for environmental protection facilities, including daily operation procedures and regular inspections, enhancing management levels and ensuring continuous improvement in environmental protection[55]. - The company has implemented pollution prevention facilities, including wastewater treatment systems and air emission treatment facilities, which are operating normally[54]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, with all energy-saving and emission reduction indicators remaining within normal ranges[60]. - The company has conducted emergency drills to enhance its response capabilities to environmental incidents, ensuring effective action can be taken in emergencies[57]. - The company has upgraded pollution control facilities and introduced advanced technologies to ensure compliance with environmental standards and reduce emissions[59]. - The company has achieved ISO 50001 energy management system certification for several high-energy-consuming enterprises, enhancing energy management measures and promoting the use of efficient equipment[61]. - The company has actively engaged in poverty alleviation and rural revitalization efforts, purchasing and selling agricultural products worth CNY 228,100 from targeted support areas[62]. Shareholder Relations - The company commits to minimizing related party transactions and ensuring fair pricing in any necessary transactions with related parties[66]. - The company guarantees to maintain independence in personnel, assets, finance, and operations post-transaction completion[68]. - The company will not require any form of guarantee from the listed company or its subsidiaries after the transaction[68]. - The company will adhere to all relevant regulations and ensure equal exercise of shareholder rights post-transaction[66]. - The company will provide priority to the listed company for any new competitive business opportunities within its operational scope[66]. - The company will not engage in any illegal occupation of the listed company's funds or assets[68]. - The company will ensure that any necessary related party transactions are conducted in compliance with legal and internal regulations[68]. - The company will bear any losses incurred by violations of commitments made to the listed company and its shareholders[68]. - The company will strictly fulfill its commitments to avoid harming the legal rights of other shareholders[66]. Financial Reporting and Compliance - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[123]. - The company has established specific accounting policies for financial instruments impairment, inventory, fixed asset depreciation, and revenue recognition[122]. - The company’s accounting year runs from January 1 to December 31[124]. - The company recognizes significant receivables and payables based on specific thresholds, such as receivables exceeding 0.03% of total assets and amounts greater than CNY 5 million[127]. - The company’s financial statements are prepared based on the principle of continuous operation[120]. Taxation and Incentives - The company has a corporate income tax rate of 15% for several subsidiaries, with some entities subject to rates of 20% and 25%[178][179]. - The value-added tax rates applicable to the company are 13%, 9%, 6%, and 5%, with small-scale taxpayers at 3% and 1%[177]. - The company has implemented a tax reduction policy allowing advanced manufacturing enterprises to deduct an additional 5% of the input VAT from the payable VAT amount until December 31, 2027[182]. - The company’s subsidiaries are eligible for various tax incentives, including a 15% income tax rate for those meeting specific criteria under national policies[181]. Accounts Receivable Management - The total accounts receivable at the end of the period is CNY 1,438,941,614.32, an increase from CNY 1,409,726,722.67 at the beginning of the period, representing a growth of approximately 2.0%[188]. - The provision for bad debts at the end of the period is CNY 69,655,210.90, with a provision ratio of 4.84%[194]. - The company reported a significant increase in accounts receivable aged 1 to 2 years, with a balance of CNY 12,140,476.79 at the end of the period, compared to CNY 6,657,992.74 at the beginning, marking an increase of approximately 82.5%[188]. - The bad debt provision for accounts receivable aged over 5 years is CNY 2,987,990.82, with a 100% provision ratio[192]. - The top five customers account for 24.81% of the total accounts receivable and contract assets, totaling CNY 356,959,025.78[195]. - The company has recognized a bad debt recovery of CNY 894,243.35 during the period, contributing to the overall bad debt provision[193]. - The provision for bad debts by individual assessment is CNY 8,015,687.68, with a 100% provision ratio for all assessed accounts[189]. - The company has a total of CNY 1,426,596,528.92 in accounts receivable aged within 1 year, with a bad debt provision of CNY 56,395,303.50, reflecting a provision ratio of 4.00%[192]. - The company has written off bad debts amounting to CNY 1,459,276.18 during the period[194]. - The total bad debt provision increased by CNY 3,877,091.20 during the period, from CNY 68,162,740.49 to CNY 69,655,210.90[194]. Investment and Capital Management - The company has a total loan amount of CNY 2,000,000, with a beginning balance of CNY 2,500,000[78]. - The company has a total of CNY 397,108,200.72 in guarantees provided to subsidiaries during the reporting period[85]. - The company has a management agreement for 61.06% equity in Guorui Pharmaceutical, with a management fee of CNY 500,000 per year for three years[81]. - The total guarantee amount provided by the company to subsidiaries was CNY 212,120,611.32, which accounts for 1.64% of the company's net assets[85]. - The company reported a total rental income of CNY 3,514,060.82 from leasing office buildings and other properties[83]. Market and Competitive Landscape - The overall economic growth rate in China for the first half of 2024 was 5.0%, with the pharmaceutical manufacturing industry experiencing a slight revenue decline of 0.9%[24]. - The company is actively pursuing market expansion and technological advancements through its subsidiaries, as evidenced by multiple high-tech certifications received recently[180]. Accounting Policies - The company applies accounting policies for revenue recognition based on the type of business, confirming revenue at the point when control of the product is transferred to the customer[169]. - For domestic sales, revenue is recognized when products are delivered and accepted by the customer, with payment received or a receipt obtained[170]. - The company recognizes government grants as deferred income when they are related to assets, and these are amortized over the useful life of the related assets[171]. - Deferred tax assets and liabilities are recognized based on the difference between the carrying amount of assets and liabilities and their tax bases, using applicable tax rates[172].

上海现代制药股份有限公司 董事、监事和高级管理人员所持本公司股份 及其变动管理制度 （2024 年 8 月 27 日经第八届董事会第十四次会议审议通过） 第一章 总则 第一条 为规范上海现代制药股份有限公司（以下简称公司或本公司）董事、 监事和高级管理人员（以下简称董监高）所持本公司股份及其变动的管理，根据 《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以 下简称《证券法》）、《上市公司董事、监事和高级管理人员所持本公司股份及其 变动管理规则》《上海证券交易所上市公司自律监管指引第 15 号——股东及董 事、监事、高级管理人员减持股份》等有关法律法规、规范性文件及《上海现代 制药股份有限公司章程》（以下简称《公司章程》），结合公司实际情况，制定本 制度。 第二条 董监高所持本公司股份，是指登记在其名下和利用他人账户持有的 所有本公司股份。 董监高从事融资融券交易的，其所持本公司股份还包括记载在其信用账户内 的本公司股份。董监高不得融券卖出本公司股份。 第三条 董监高在买卖本公司股票及其衍生品种前，应知悉《公司法》《证券 法》等法律、法规关于内幕交易、操纵市场等禁止行为的规定，不得进 ...

证券代码：600420 证券简称：国药现代 公告编号：2024-059 公司 2024 年半年度报告全文及摘要详见 www.sse.com.cn。 2、审议通过了《2024 年中期利润分配方案》。 上海现代制药股份有限公司 第八届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海现代制药股份有限公司（以下简称公司）第八届董事会第十四次会议， 于 2024 年 8 月 27 日在上海市浦东新区建陆路 378 号以现场结合通讯会议的方 式召开。本次会议的通知和会议资料已于 2024 年 8 月 16 日以电子邮件方式发 出。本次会议应参会董事 9 名，实际参会董事 9 名。会议由董事长董增贺先生主 持，公司部分监事和高级管理人员列席了会议。本次会议的召集和召开程序符合 《公司法》和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 本次会议审议并通过了如下事项： 1、审议通过了《2024 年半年度报告及摘要》。 本议案已经董事会审计与风险管理委员会 2024 年第四 ...

证券代码：600420 证券简称：国药现代 公告编号：2024-061 上海现代制药股份有限公司 关于 2024 年中期利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 分配比例：每10股派发现金股利1.00元（含税）。 本次利润分配以2024年6月30日总股本1,341,172,692股为基数，共计分 配现金股利134,117,269.20元（含税）。 一、利润分配方案内容 1、2024 年 5 月 28 日，公司召开 2023 年年度股东大会审议通过了《关于 2024 年中期分红安排的议案》，同意公司 2024 年半年度结合未分配利润与当期 业绩进行中期分红，并授权董事会在满足上述利润分配条件的情况下，制定具体 的 2024 年中期分红方案，在规定期限内实施。 2、2024 年 8 月 27 日，公司召开第八届董事会第十四次会议，以 9 票同意， 0 票反对，0 票弃权的表决结果，审议通过了《2024 年中期利润分配方案》。 3、2024 年 8 月 27 日，公司召开第八届监事会第九次会 ...

证券代码：600420 证券简称：国药现代 公告编号：2024-060 上海现代制药股份有限公司 第八届监事会第九次会议决议公告 2、审议通过了《2024 年中期利润分配方案》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本次会议审议并通过了如下事项： 1、审议通过了《2024 年半年度报告及摘要》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 监事会就公司 2024 年半年度报告确认如下：公司 2024 年半年度报告的编制 和审议程序符合法律、法规及公司内部相关管理制度的规定，真实、准确、完整 地反映了公司 2024 年半年度的财务状况和经营成果，其中不存在虚假记载、误 导性陈述或重大遗漏。 公司 2024 年半年度报告全文及摘要详见 www.sse.com.cn。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海现代制药股份有限公司（以下简称公司）第八届监事会第九次会议，于 2024 年 8 月 27 日在上海市浦东新区建陆路 378 号以视频通讯的方式召开。本次 会议的通 ...

证券代码：600420 证券简称：国药现代 公告编号：2024-063 上海现代制药股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 （四） 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 9 月 12 日 14 点 00 分 召开地点：上海市浦东新区建陆路 378 号 B1 楼五楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 9 月 12 日 至 2024 年 9 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 ...

上海现代制药股份有限公司 关于国药集团财务有限公司 2024 年半年度风险持续评估的报告 根据《上海证券交易所上市公司自律监管指引第 5 号—交易与关联交易》的 要求，通过查验国药集团财务有限公司（以下简称国药财务）的《营业执照》与 《金融许可证》等资料，并审阅了国药财务 2024 年半年度的财务报告以及风险 指标等必要信息，上海现代制药股份有限公司（以下简称国药现代）对国药财务 的经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、国药财务基本情况 国药财务成立于2012年2月23日，是经中国银行保险监督管理委员会批准成 立的非银行金融机构。 注册地址：北京市海淀区知春路20号 法定代表人：杨珊华 二、国药财务内部控制的基本情况 （一）控制环境 国药财务已经建立了内部控制制度体系。包括：《公司章程》、各项管理制度 和业务操作流程等。《公司章程》确定了成立公司的基本原则，明确股东的出资 方式，确定了公司的经营范围，对股东的权利和义务进行界定，规范了股东会、 董事会和监事会的职权和议事规则，对经营管理机构管理模式进行规定，强调了 监督管理与风险控制的重要性。《授权管理办法》规范了公司授权管理基本体系， ...